metastatic pancreatic ductal adenocarcinoma
Conditions
Interventions
BI 765883 in monotherapy or in combination with gemcitabine and nab-paclitaxel.
Sponsors
Nakahara Asuka
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: -Histologically or cytologically confirmed Pancreatic ductal adenocarcinoma (PDAC) -Eastern Cooperative Oncology Group (ECOG) performance status 0 to1 -Life expectancy more than months in the opinion of the investigator -Archived tumor tissue from a tissue core biopsy (e.g. paraffin-embedded formalin-fixed tissue blocks), OR fresh tumor tissue available for retrospective biomarker analysis; in both cases, a minimum of at least two core needle biopsies (18 gauge or greater) is required. Only non-significant risk procedures per the investigator's judgment will be used to obtain any biopsies specified in this study in cases where a fresh tumor biopsy is required. -Patients with at least 1 target lesion that can be accurately measured per RECIST version 1.1 -Further inclusion criteria apply.
Exclusion criteria
Exclusion criteria: -Previous exposure to trial drug (BI 765883) -Any prior gemcitabine and/or paclitaxel therapy (for combination therapy cohorts) -Known hypersensitivity to the study medications or their excipients (including gemcitabine and nab-paclitaxel) -Any contraindications to gemcitabine or nab-paclitaxel according to the current approved local labels (combination therapy) -Currently enrolled in another investigational device or drug trial, or less than 28 days since ending another investigational device or drug trial(s) or receiving other investigational treatment(s) -Any serious concomitant disease or medical condition affecting compliance with trial requirements or which are considered relevant for the evaluation of the efficacy or safety of the trial drug, such as neurologic, psychiatric, infectious disease, active ulcers (gastrointestinal tract, skin), inflammatory bowel disease or bowel infection, or laboratory abnormality that may increase the risk associated with trial participation or trial drug administration, and in the judgment of the Investigator, would make the patient inappropriate for entry into the trial. -Prior radiotherapy or systemic therapy within 14 days prior to treatment start -History or presence of cardiovascular abnormalities such as uncontrolled hypertension, congestive heart failure NYHA classification of III or IV, unstable angina or poorly controlled arrhythmia which are considered as clinically relevant by the Investigator -Further exclusion criteria apply.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Occurrence of DLTs in the MTD evaluation period for the determination of the MTD | — |
Countries
Belgium, France, Germany, Japan, Spain, US
Contacts
Public ContactTetstuya Katakabe
Nippon Boehringer Ingelheim Co., Ltd
Outcome results
None listed